A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

Exclusion Criteria

• •Prior exposure to any anti-PD-1 or anti-PD-L1 antibody
• •Brain metastases or spinal cord compression or unless asymptomatic, treated and stable (not requiring steroids).
• •Active or prior autoimmune disease or history of immunodeficiency
• •Evidence of severe or uncontrolled systemic diseases, including active bleeding diatheses or active infections including hepatitis B, C and HIV.
• •Evidence of uncontrolled illness such as symptomatic congestive heart failure, uncontrolled hypertension or unstable angina pectoris.
• •Any unresolved toxicity CTCAE \>Grade 2 from previous anti-cancer therapy.
• •Any prior Grade ≥3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE \>Grade 1
• •Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis)